E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Multiple System Atrophy of the Parkinsonian Subtype |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10064060 |
E.1.2 | Term | Multiple system atrophy |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To test the clinical effect of rasagiline on subjects with MSA of the parkinsonian subtype. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
both studies are part of the same protocol (MSA-RAS-202) Imaging Substudy To determine and compare rate of progression of putaminal abnormalities as assessed by diffusion weighted imaging (DWI) abnormalities in MSA-P subjects treated with rasagiline versus those treated with placebo. To determine and compare rate of progression of DWI abnormalities of different brain regions (pons, cerebellum, middle cerebellar peduncle [MCP], caudate nucleus, globus pallidum) other than the putamen in MSA-P subjects treated with rasagiline versus those treated with placebo. To determine and compare rate of progression of MSA-P-related structural changes in the putamen and brainstem on standard T2- and T1-weighted sequences of MRI.
|
|
E.3 | Principal inclusion criteria |
1.Subjects over 30 years old with a diagnosis of Possible or Probable MSA of the parkinsonian subtype (MSA-P) according to The Gilman Criteria (2008). 2.Subjects who are less than 3 years from the time of documented MSA diagnosis. 3.Subjects with an anticipated survival of at least 3 years in the opinion of the investigator. 4.Subjects who are willing and able to give informed consent. Subjects who are not able to write may give verbal consent in the presence of at least one witness, and the witness should sign the informed consent form.
|
|
E.4 | Principal exclusion criteria |
1. Subjects receiving treatment with midodrine or other sympathomimetics within 4 weeks prior to baseline visit. 2. Subjects with severe orthostatic symptoms as assessed by a score of ≥ 3 on UMSARS question 9. 3. Subjects who meet any of the following criteria which tend to suggest advanced disease: a.Speech impairment as assessed by a score of ≥ 3 on UMSARS question 1 b.Swallowing impairment as assessed by a score of ≥ 3 on UMSARS question 2 c.Impairment in ambulation as assessed by a score of ≥ 3 on UMSARS question 7 d.Falling more frequently than once per week as assessed by a score of ≥ 3 on UMSARS question 8 4. Subjects taking disallowed medications according to the locally approved Azilect® label. 5. Subjects taking MAO inhibitors within 3 months prior to baseline visit. 6. Subjects with hypertension whose blood pressure, in the investigator’s opinion, is not well controlled. 7. Subjects who, based on the investigator’s judgment, have a clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation. Subjects with moderate or severe hepatic impairment. 8. Subjects who have taken any investigational products within 60 days prior to baseline. 9. Women of child-bearing potential who do not practice a highly efficient method of birth control with a failure rate of less than 1%, when used consistently and correctly. [Highly efficient methods of birth control in this study include: surgical sterilization, contraceptive patch, hormonal intrauterine devices (hormone contraceptive coil), long-acting injectable contraceptive, hormone-releasing vaginal ring, hormone implant or partner's vasectomy.] In general, oral contraceptives also have a failure rate of less than 1%. In case of diarrhea or vomiting they are not considered to be highly efficient until the following menstruation. Methods of birth control which are not considered to be highly efficient: coil, intrauterine pessary, LEA contraceptive or condom, even in combination with spermicide (double barrier method). 10. Pregnant or nursing women.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change from baseline to Week 48/Termination visit in the total UMSARS score (the total UMSARS score is defined as the sum of Parts I + II) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 20 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
termination visit at week 48 |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |